627 related articles for article (PubMed ID: 15847853)
1. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
Goldsmith SR
Am J Cardiol; 2005 May; 95(9A):14B-23B. PubMed ID: 15847853
[TBL] [Abstract][Full Text] [Related]
2. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms, risks, and new treatment options for hyponatremia.
Ghali JK
Cardiology; 2008; 111(3):147-57. PubMed ID: 18434717
[TBL] [Abstract][Full Text] [Related]
4. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism.
Rai A; Whaley-Connell A; McFarlane S; Sowers JR
Am J Nephrol; 2006; 26(6):579-89. PubMed ID: 17170524
[TBL] [Abstract][Full Text] [Related]
5. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
6. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Palm C; Pistrosch F; Herbrig K; Gross P
Am J Med; 2006 Jul; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
[TBL] [Abstract][Full Text] [Related]
7. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.
LeJemtel TH; Serrano C
Int J Cardiol; 2007 Aug; 120(1):1-9. PubMed ID: 17346825
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for hyponatremia in heart failure.
Goldsmith SR
Congest Heart Fail; 2010 Jul; 16 Suppl 1():S15-8. PubMed ID: 20653706
[TBL] [Abstract][Full Text] [Related]
9. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
[TBL] [Abstract][Full Text] [Related]
10. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
Abraham WT; Shamshirsaz AA; McFann K; Oren RM; Schrier RW
J Am Coll Cardiol; 2006 Apr; 47(8):1615-21. PubMed ID: 16630999
[TBL] [Abstract][Full Text] [Related]
11. Hyponatremia: current treatment strategies and the role of vasopressin antagonists.
Cawley MJ
Ann Pharmacother; 2007 May; 41(5):840-50. PubMed ID: 17405824
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin and vasopressin receptor antagonists in heart failure.
Oghlakian G; Klapholz M
Cardiol Rev; 2009; 17(1):10-5. PubMed ID: 19092365
[TBL] [Abstract][Full Text] [Related]
13. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA
J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593
[TBL] [Abstract][Full Text] [Related]
14. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
Patel GP; Balk RA
Clin Ther; 2007 Feb; 29(2):211-29. PubMed ID: 17472815
[TBL] [Abstract][Full Text] [Related]
15. Hyponatremia in congestive heart failure.
Oren RM
Am J Cardiol; 2005 May; 95(9A):2B-7B. PubMed ID: 15847851
[TBL] [Abstract][Full Text] [Related]
16. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin: a new target for the treatment of heart failure.
Lee CR; Watkins ML; Patterson JH; Gattis W; O'connor CM; Gheorghiade M; Adams KF
Am Heart J; 2003 Jul; 146(1):9-18. PubMed ID: 12851603
[TBL] [Abstract][Full Text] [Related]
19. Vasopressin excess and hyponatremia.
Pham PC; Pham PM; Pham PT
Am J Kidney Dis; 2006 May; 47(5):727-37. PubMed ID: 16632011
[TBL] [Abstract][Full Text] [Related]
20. Vaptans and the treatment of water-retaining disorders.
Quittnat F; Gross P
Semin Nephrol; 2006 May; 26(3):234-43. PubMed ID: 16713496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
